An AP-1 Binding Site in the Enhancer/Core Element of the HIV-1 Promoter Controls the Ability of HIV-1 To Establish Latent Infection

被引:80
作者
Duverger, Alexandra [1 ]
Wolschendorf, Frank [1 ]
Zhang, Mingce [1 ]
Wagner, Fredric [1 ]
Hatcher, Brandon [2 ]
Jones, Jennifer [1 ]
Cron, Randall Q. [1 ]
van der Sluis, Renee M. [3 ]
Jeeninga, Rienk E. [3 ]
Berkhout, Ben [3 ]
Kutsch, Olaf [1 ]
机构
[1] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA
[3] Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, Lab Expt Virol,Ctr Infect & Immun Amsterdam CINIM, NL-1105 AZ Amsterdam, Netherlands
关键词
HUMAN-IMMUNODEFICIENCY-VIRUS; CD4(+) T-CELLS; NF-KAPPA-B; LONG TERMINAL REPEAT; HISTONE DEACETYLASE INHIBITION; ACTIVE ANTIRETROVIRAL THERAPY; TRANSCRIPTIONAL ACTIVATION; RESPONSIVE ELEMENT; GENE-EXPRESSION; TYPE-1; SUBTYPES;
D O I
10.1128/JVI.01594-12
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Following integration, HIV-1 in most cases produces active infection events; however, in some rare instances, latent infection events are established. The latter have major clinical implications, as latent infection allows the virus to persist despite antiretroviral therapy. Both the cellular factors and the viral elements that potentially determine whether HIV-1 establishes active or latent infection events remain largely elusive. We detail here the contribution of different long terminal repeat (LTR) sequences for the establishment of latent HIV-1 infection. Using a panel of full-length replication-competent virus constructs that reflect naturally occurring differences of HIV-1 subtype-specific LTRs and targeted LTR mutants, we found the primary ability of HIV-1 to establish latent infection in this system to be controlled by a four-nucleotide (nt) AP-1 element just upstream of the NF-kappa B element in the viral promoter. Deletion of this AP-1 site mostly deprived HIV-1 of the ability to establish latent HIV-1 infection. Extension of this site to a 7-nt AP-1 sequence massively promoted latency establishment, suggesting that this promoter region represents a latency establishment element (LEE). Given that these minimal changes in a transcription factor binding site affect latency establishment to such large extent, our data support the notion that HIV-1 latency is a transcription factor restriction phenomenon.
引用
收藏
页码:2264 / 2277
页数:14
相关论文
共 80 条
[21]   Catalytic activity of the proteasome fine-tunes Brg1-mediated chromatin remodeling to regulate the expression of inflammatory genes [J].
Cullen, Sarah J. ;
Ponnappan, Subramaniam ;
Ponnappan, Usha .
MOLECULAR IMMUNOLOGY, 2009, 47 (2-3) :600-605
[22]   Determinants of the Establishment of Human Immunodeficiency Virus Type 1 Latency [J].
Duverger, Alexandra ;
Jones, Jennifer ;
May, Jori ;
Bibollet-Ruche, Frederic ;
Wagner, Frederic A. ;
Cron, Randall Q. ;
Kutsch, Olaf .
JOURNAL OF VIROLOGY, 2009, 83 (07) :3078-3093
[23]   Short Communication: Activation of Latent HIV Type 1 Gene Expression by Suberoylanilide Hydroxamic Acid (SAHA), an HDAC Inhibitor Approved for Use to Treat Cutaneous T Cell Lymphoma [J].
Edelstein, Leonard C. ;
Micheva-Viteva, Sophia ;
Phelan, Bradley D. ;
Dougherty, Joseph P. .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2009, 25 (09) :883-887
[24]  
ELIOPOULOS AG, 1993, INT J ONCOL, V2, P883
[25]   A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency [J].
Emiliani, S ;
VanLint, C ;
Fischle, W ;
Paras, P ;
Ott, M ;
Brady, J ;
Verdin, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (13) :6377-6381
[26]   HIV-1 TAT TRANS-ACTIVATION REQUIRES THE LOOP SEQUENCE WITHIN TAR [J].
FENG, S ;
HOLLAND, EC .
NATURE, 1988, 334 (6178) :165-167
[27]   Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy [J].
Finzi, D ;
Blankson, J ;
Siliciano, JD ;
Margolick, JB ;
Chadwick, K ;
Pierson, T ;
Smith, K ;
Lisziewicz, J ;
Lori, F ;
Flexner, C ;
Quinn, TC ;
Chaisson, RE ;
Rosenberg, E ;
Walker, B ;
Gange, S ;
Gallant, J ;
Siliciano, RF .
NATURE MEDICINE, 1999, 5 (05) :512-517
[28]   Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy [J].
Finzi, D ;
Hermankova, M ;
Pierson, T ;
Carruth, LM ;
Buck, C ;
Chaisson, RE ;
Quinn, TC ;
Chadwick, K ;
Margolick, J ;
Brookmeyer, R ;
Gallant, J ;
Markowitz, M ;
Ho, DD ;
Richman, DD ;
Siliciano, RF .
SCIENCE, 1997, 278 (5341) :1295-1300
[29]   A new reporter cell line to monitor HIV infection and drug susceptibility in vitro [J].
Gervaix, A ;
West, D ;
Leoni, LM ;
Richman, DD ;
WongStaal, F ;
Corbeil, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (09) :4653-4658
[30]   The regulation of HIV-1 gene expression: The emerging role of chromatin [J].
He, GC ;
Ylisastigui, L ;
Margolis, DM .
DNA AND CELL BIOLOGY, 2002, 21 (10) :697-705